Guidelines from the European leukemia network (ELN) in 2017 indicated that molecular abnormalities in genes such as NPM1, FLT3-ITD, CEBPA, RUNX1, TP53, and ASXL1 combined with karyotype abnormalities can be used as an effective and comprehensive stratification system for the diagnosis and treatment of AML (4). This evidence concerns the gene RUNX1 and acute myeloid leukemia.